AustinPX
111 W. Cooperative Way, Building 3
Georgetown
Texas
78626
United States
9 articles about AustinPX
-
AustinPx Partners with Microsize on KinetiSol® Technology
1/31/2024
AustinPx and Microsize announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform.
-
DisperSol Technologies Announces Collaboration with Ajax Therapeutics to Develop Enhanced KinetiSol Drug Formulations
12/17/2021
DisperSol Technologies LLC announced today that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies.
-
DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline
8/2/2021
DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.
-
DisperSol Technologies Promotes Dave Miller to Chief Scientific Officer
7/14/2021
DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.
-
DisperSol Technologies Promotes Chris Brough to Chief Technology Officer
7/14/2021
DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.
-
DisperSol Technologies Names David Snyder as Chief Financial Officer
9/24/2020
DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar
-
DisperSol Technologies Raising $27 Million and Initiating Phase II Trials of DST-0509 in Iron Overload Disorder
4/26/2018
DisperSol Technologies, LLC, has secured commitments for $27 million in equity financing.
-
DisperSol Technologies Announces New R&D Data to Be Presented at 2017 Annual Meeting of AAPS
11/9/2017
The symposium will highlight partners' experiences with KinetiSol: a novel manufacturing technology for making amorphous solid dispersions of poorly water-soluble drug molecules to enhance their bioavailability & clinical effectiveness.
-
DisperSol Names Dr. Edward M. Rudnic As Chief Executive Officer, RCT Leads $12 Million Funding Round
11/9/2016